T
he mass media and the medical literature have been saturated in the last few years by concerns about a variety of emerging viral epidemics such as Ebola and Zika. We must always remember that infl uenza will continue to affect many more patients worldwide.
The Cleveland Clinic Journal of Medicine periodically publishes updates on infl uenza, a topic befi tting the large proportion of internists and internal medicine subspecialists who regularly read the Journal. This series began in 1975 with an article by Steven R. Mostow, MD, 1 which followed three pandemics that changed the world's attitude about infl uenza. A lot has changed since then, including another pandemic in [2009] [2010] . Here, I review recent information relevant to daily practice.
■ NO REASON FOR COMPLACENCY
The relatively mild 2015-2016 infl uenza season is no reason for complacency this season.
Infl uenza activity in 2015-2016 was milder than in most seasons in the last decade. 2 Activity peaked in mid-March and resulted in fewer outpatient visits, hospitalizations, and deaths than in previous seasons. Infl uenza A (H1N1)pdm09 has remained the predominant circulating virus since 2009. Although the overall rate of infl uenza-related hospitalization was less than half that in previous years, the hospitalization rate of middle-aged adults was relatively high (16.8 per 100,000 population). Importantly, 92% of adults with infl uenza illness that required hospitalization had at least one underlying medical condition, alerting us as healthcare providers that there is plenty of room for improvement in preventing such hospitalizations. 
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ABSTRACT
Infl uenza kills and hospitalizes many people every year. Although the 2015-2016 infl uenza season was relatively mild, we should remain vigilant in our efforts to reduce the impact of future epidemics or pandemics by implementing universal infl uenza vaccination and early initiation of antiviral therapy for suspected cases. We don't expect infl uenza vaccine to prevent all cases of infl uenza, since immune response varies depending on age, underlying diseases, and immunosuppression.
KEY POINTS
Infl uenza vaccine remains the most effective way to prevent infl uenza. Healthcare providers should continue to vaccinate all people older than 6 months.
For the 2016-2017 infl uenza season, only the inactivated infl uenza vaccine, not the live-attenuated vaccine, is recommended, regardless of age group or underlying disease.
Early initiation of a neuraminidase inhibitor is advised for an infl uenza-like illness while awaiting a confi rmatory diagnostic test.
MOSSAD
We should remain vigilant. We should put forth our best efforts in vaccinating all individuals above the age of 6 months and in diagnosing infl uenza early in the course of the illness in order to prescribe antiviral therapy within 48 hours of onset of symptoms. These actions not only shorten the illness and prevent hospitalization and secondary bacterial infection, but also reduce contagion and thus reduce overall healthcare costs.
School closure as a measure to halt epidemics has been lately called into question, 3 since there are not enough data to support doing this routinely. School closure in Western Kentucky during the 2013 infl uenza epidemic did not reduce transmission but caused additional economic and social diffi culties for certain households. 4 ■ STUDIES REINFORCE EARLIER DATA THAT INFLUENZA VACCINE WORKS In the several decades since infl uenza vaccine became available, hundreds of studies have demonstrated the value of the "fl u shot." A few recent papers that support these wellestablished data:
• In adults who sought medical care for acute respiratory illness, infl uenza vaccine was 58.4% effective in preventing laboratoryconfi rmed infl uenza illness in adults age 50 and older. 5 • In the same age group, infl uenza vaccine was 56.8% effective in preventing laboratory-confi rmed infl uenza hospitalizations. 6 • Influenza vaccination in patients with heart failure reduced all-cause hospitalizations, particularly cardiovascular hospitalizations (30% reduction) and hospitalizations for respiratory infections (16% reduction). 7 This effect lasted up to 4 months after influenza vaccination.
• Patients who were hospitalized with community-acquired, laboratory-confi rmed infl uenza pneumonia were 43% less likely to have received the infl uenza vaccine than patients hospitalized with communityacquired pneumonia due to other pathogens. 8 
■ INFLUENZA VACCINE IS EVEN MORE VALUABLE DURING PREGNANCY
Infl uenza vaccination during pregnancy prevented one in fi ve preterm deliveries in a developing country 9 and reduced the risk of stillbirth by 50% in Australia. 10 An interesting collateral benefi t was demonstrated in a survey conducted in Minnesota, where children of mothers who self-reported prenatal infl uenza vaccination were more likely to complete their routine childhood vaccination series.
■ ADDITIONAL BENEFITS OF INFLUENZA VACCINATION
A recently appreciated benefi t is that infl uenza vaccine induces cross-reactive protective immune responses ("heterologous immunity") to viral strains not included in the vaccine, even in immunosuppressed individuals such as kidney transplant recipients. 12 Interestingly, patients were more likely to seroconvert for a cross-reactive "heterologous" antigen if they also seroconverted for the vaccine-specifi c "homologous" antigen.
In a study in mice, an infl uenza vaccine with an adjuvant protected mice not only from infl uenza virus challenge, but also from a Staphylococcus aureus superinfection challenge. 13 This novel idea suggests that infl uenza vaccine protects not only against infl uenza virus infection, but also against a potentially fatal secondary bacterial infection. This has signifi cant implications for curbing antibacterial use, with an expected reduction in antimicrobial resistance.
Another important benefi t of infl uenza vaccination was recently demonstrated when ferrets were intranasally inoculated with the highly pathogenic infl uenza A(H5N1) strain and then received either infl uenza vaccine or prophylactic oseltamivir. Ferrets that received the vaccine were less likely to develop severe meningoencephalitis.
14 Since infl uenza A(H5N1) is much more virulent than the current circulating infl uenza strains, and since it may be the cause of the next pandemic, preventing such a serious complication of infl uenza would be lifesaving. Issues related to Guillain-Barré syndrome have long been put to rest. A large retrospective study found no evidence of increased risk of Guillain-Barré syndrome following vaccination of any kind, including infl uenza vaccination. 15 Local reactions after vaccination are transient and do not interfere with the ability to perform daily activities.
In this era of utilization review, it is reassuring to know that giving infl uenza vaccine to hospitalized surgical patients was not associated with an increased rate of postdischarge fever or other clinical concern for infection requiring emergency room visits or rehospitalization. 16 
■ WHY INFLUENZA VACCINE MAY NOT PREVENT ALL CASES OF INFLUENZA
Whether neutralizing antibodies to infl uenza virus hemagglutinin antigen should be the main immune correlate of protection for infl uenza vaccines remains in question. Although prepandemic avian infl uenza vaccines are poorly immunogenic in inducing neutralizing antibodies, they confer considerable protection. A recent study showed that antibody-dependent cell-mediated cytotoxicity to hemagglutinin antigen in an avian infl uenza vaccine was a better predictor of protective capacity than neutralizing antibodies. 17 Patterns of immunity induced by the liveattenuated infl uenza vaccine and the inactivated infl uenza vaccine are different. 18 In fact, no single cytokine or chemokine measurement predicts protection.
Even though adults age 50 and older mount statistically signifi cant humoral and cell-mediated immune responses to the inactivated vaccine, two-thirds do not reach hemagglutination inhibition antibody titers of 40 or higher for infl uenza A(H1N1), and one-fi fth do not reach hemagglutination inhibition antibody titers of 40 or higher for infl uenza A(H3N2). 19 While age had some negative effect on vaccine responsiveness, prevaccination titers were much better at predicting postvaccination antibody levels.
■ ONGOING DEBATE OVER LIVE-ATTENUATED INFLUENZA VACCINE
Several studies had shown that the live-attenuated infl uenza vaccine, given intranasally, was not only more protective in vaccinated children, but also provided herd protection in unvaccinated contacts. However, a recently published study conducted in Canadian Hutterite children showed that the live-attenuated vaccine did not result in herd immunity when compared to the inactivated infl uenza vaccine. 20 On June 22, 2016, the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended against the use of the live-attenuated vaccine for the 2016-2017 season, 21 based on data showing negligible protection conferred by the live-attenuated infl uenza vaccine in the three preceding infl uenza seasons.
This decision created signifi cant debate among experts in the fi eld. It is unclear why the live-attenuated infl uenza vaccine was much less protective in the last three seasons than in prior seasons. Recommending against its use in the United States will essentially eliminate any possibility of reassessing its efficacy in this country. Of note, the quadrivalent live-attenuated infl uenza vaccine had recently replaced the previous trivalent live-attenuated vaccine, which may have introduced some "competition" among the vaccine strains to infect enough cells to allow viral replication and subsequent immune response. Another potential explanation is that consistent annual vaccination may have resulted in a cumulative immunity that could hamper response to subsequent doses. Infl uenza vaccine manufacturers estimated they would produce 170 million doses for distribution in the United States for the upcoming infl uenza season. The previously mentioned recommendation against the use of the live-attenuated vaccine, which accounts for approximately 8% of the infl uenza vaccine supply, may affect vaccine uptake, particularly in children.
■ NEW ANTI-INFLUENZA AGENTS AND UPDATE ON EXISTING AGENTS
Neuraminidase inhibitors are the only class of antiviral drugs currently recommended for prevention and treatment of infl uenza. The three products currently available in the United States are oseltamivir, zanamivir, and peramivir. Oseltamivir is administered orally, and the fi rst generic version was approved by the US Food and Drug Administration on August 3, 2016. Zanamivir is administered by oral inhalation. Both oseltamivir and zanamivir are approved for treatment and prevention of infl uenza. Peramivir is administered intravenously as a single dose and is approved only for the treatment of acute infl uenza, not prevention. Unfortunately, the infl uenza vaccination rate during pregnancy in the United States remains only around 50%. 23 Physicians' recommendations are strongly associated with vaccine uptake, particularly when they emphasize protective effect on the newborn. Infl uenza during pregnancy carries higher mortality than in the general population, with collateral fetal loss.
Early initiation of antiviral therapy is particularly imperative during pregnancy. A recent study showed that starting antiviral therapy within 2 days of onset of illness in pregnant women hospitalized with severe infl uenza reduced length of stay by 5.6 days compared with those in whom therapy was started more than 2 days after illness onset. 24 A single dose of laninamivir octanoate, a long-acting neuraminidase inhibitor currently approved in Japan for treating infl uenza, was recently shown to be effective as postexposure prophylaxis. 25 This option may be convenient for people who prefer not to take a daily medication for several days, or in an outbreak in a healthcare facility. ■
